Abstract
Human low density lipoproteins (LDL), the major carriers of cholesterol in the bloodstream, plays the major role in supplying cells of tissues and organs with cholesterol. It is derived from the metabolism of the triglyceride-rich very low density lipoproteins (VLDL). Pathologic and epidemiologic studies have implicated that higher concentration of LDL in circulation is correlated with the development of atherosclerosis. Apolipoprotein (apo) B-100 serves as the ligand for the LDL receptor on cell surfaces. Thus, apoB-100 occupies a crucial position in the metabolic pathway of cholesterol and LDL. The complete primary structure of apoB-100 has been determined from its cDNA sequence (Chen et al., 1986; Knott,et al, 1986) and from its proteolytic peptide sequence information (Yang, et. al, 1986). ApoB-100 consists of 4536 amino acid residues with a calculated molecular mass of 513 kDa. Based on the differential trypsin releasibility of apoB-100 in LDL, apoB can be divided into 5 domains. Domain 1 contains 14 of the 25 cysteine (Cys) residues in apoB. Sixteen of the 25 Cys residues (which are numbered from 1 to 25 from the amino end to the carboxy end in apoB-100) exist in disulfide form. All 14 Cys residues in domain 1 are linked in disulfide form, and all except Cys 1-Cys3 and Cys2-Cys4 are linked to neighboring Cys. Domain 4 contains 7 of the 16 N-glycosylated carbohydrates (Yang et al., 1989). Based on the published structural information (Yang et al., 1990), we proposed that the structure of apoB-100 in LDL is likely to be an elongated form that wraps around the LDL molecule as shown in Fig. 1 (Yang et al., 1992). The process of atherogenesis is believed to involve transformation of macrophages to lipid-laden foam cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chen, S.-H., Yang, C.-Y., Chen, P.-F., Setzer, D., Tanimura, M., Li, W.-H., Gotto, A.M., Jr., and Chan, L., 1986, The complete cDNA and amino acid sequence of human apolipoprotein B-100, J. Biol. Chem., 261: 12918.
Fievet, C., Durieux, C., Milne, R., Delaunay, T., Agnani, G., Bazin, H, Marcie, Y., and Fruchart, J.C., 1989, Rat monoclonal antibodies to human apolipoprotein B: advantages and applications. J. Lipid Res. 30, 1015–1024
Gandjini, H., Gambert, P., Athias, A., and Lallemant, C., 1991, Resistance to LDL oxidative modifications of an N-terminal apolipoprotein B epitope. Atherosclerosis 89, 83–93.
Goldstein, J.L., Ho, Y.K., Basu, S.K., and Brown, M.S., 1979, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76, 333–337.
Henriksen, T., Mahoney, E.M., and Steinberg, D. 1983, Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 3, 149–159.
Knott, T.J., Pease, R.J., Powell, L.M., Wallis, S.C., Rail, S.C., Jr., Innerarity, T.L., Blackhart, B., Taylor, W.H., Marcel, Y.L., Milne, R.W., Johnson, D., Fuller, M., Lusis, A.J., McCarthy, B.J., Mahley, R.W., Levy-Wilson, B., and Scott, J.L., 1986, Complete protein sequence and identification of structural domains of human apolipoprotein B, Nature (London) 323: 734.
Negri, S., Roma, P., Fogliatto, R., Uboldi, P., Marcovina, S., and Catapano, A.L., 1993, Immunoreactivity of apo B towards monoclonal antibodies that inhibit the LDL-receptor interaction: effects of LDL oxidation. Atherosclerosis 101, 37–41.
Pease, R.J., Milne, R.W., Jessup, W.K., Law, A., Provots, P., Fruchart, J.C., Dean, R.T., Marcel, Y.L., and Scott, J., 1990, Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J. Biol. Chem. 265: 553–568.
Salmon, S., Goldstein, S., Pastier, D., Theron, L., Berthelier, M., Ayrault-Jarrier, M., Dubarry, M., Rebourcet, R., and Pau, B., 1984, Monoclonal antibodies to low density lipoprotein used for the study of low-and very-low-density lipoproteins, in “ELISA” and immunoprecipitation techniques. Biochim. Biophys. Res. Commun. 125: 704–711.
Steinbrecher, U.P., Parthasarathy, S., Leake, D.S., Witztum, J.L., and Steinberg, S., 1984, Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81: 3883–3887.
Steinbrecher, U.P, Witztum, J.L., Parthasarathy, S., and Steinberg, D. (1987). Decrease in reactive amino groups diring oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 7, 135–143.
Valentinova, N.V., Gu, Z.W., Yang, M., Yanushevskaya, E.V., Antonov, I.V., Guyton, J.R., Smith, C.V., Gotto, A.M. Jr., and Yang C.Y. (1994) Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. Biological. Chemistry Hoppe-Seyler in print.
Yang, C.Y., Chen, S.-H., Gianturco, S.H., Bradley, W.A., Sparrow, J.T., Tanimura, M., Li, W.-H., Sparrow, D.A., DeLoof, H., Rosseneu, M., Lee, F.-S., Gu, Z.-W., Gotto, A.M., Jr., and Chan, L., 1986, Sequence, Structure, Receptor Binding Domains and Internal Repeats of Human Apolipoprotein B-100, Nature (London), 323: 734.
Yang, C.-Y, Gu, Z.-W., Weng, S.-A., Kim, T.W., Chen, S.-H., Pownall, H.J., Sharp, P.M., Liu, S.-W., W-H., Gotto, A.M., Jr., and Chan, L., 1989, Structure of apolipoprotein B-100 of human low density lipoproteins, Arteriosclerosis 9: 96.
Yang, C.-Y., Kim, T.W., Weng, S.-E., Lee, B., Yang, M., and Gotto, A.M., Jr., 1990, Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100, Proc. Natl. Acad. Sci. U.S.A., 87: 5523.
Yang, C.-Y. and Pownall, H.J. Structure and function of apolipoprotein B. In Structure and Function of Plasma Apolipoproteins. (M. Rosseneu, Ed.), CRC Press, Inc. 63–84 (1992).
Yang, C.Y., Gu, Z.W., Valentinova, N., Pownall, H.J., Lee, B., Yang, M., Xie, Y.H., Guyton, J.R., Vlasik, T.N., Fruchart, J.C., and Gotto, A.M., Jr. (1993). Human very-low-density lipoprotein structure: interaction of the C apolipoproteins with apolipoprotein B-100. J. Lipid Res. 34, 1311–1321.
Yanushevskaya, E.V., Vlasik, T.N., Valentinova, N.V., Medvedeva, N.V., Fantappie, S., and Catapano, A.L. (1993). Monoclonal antibodies as a specific tool for studying apo B conformation. Abstracts for 62nd EAS Congress, Jerusalem, Israel, p. 68.
Young, S.G., Witztum, J.L., Casal, D.C., Curtiss, L.K., and Bernstein, S. (1986a). Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis 6, 178–188.
Zawadzki, Z., Milne, R.W., Marcel, Y.L. (1989). An immunochemical marker of low density lipoprotein oxidation. J. Lipid Res 30, 885–891.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yang, CY., Valentinova, N.V., Yang, M., Gu, ZW., Guyton, J.R., Gotto, A.M. (1995). Immunological Approach to Study the Structure of Oxidized Low Density Lipoproteins. In: Atassi, M.Z., Appella, E. (eds) Methods in Protein Structure Analysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1031-8_28
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1031-8_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1033-2
Online ISBN: 978-1-4899-1031-8
eBook Packages: Springer Book Archive